21 July 2009
Sita Shah
sita.shah@informa.com
Merck & Co's second-quarter net income fell by 12%, hit by negative currency effects and poor sales of its cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe plus simvastatin).
However, it has reaffirmed its 2009 GAAP EPS guidance of $2.84-$3.09 and full-year revenue forecasts of...
Please Login to read the full article.
RELATED CONTENT
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
